1. Abal M, Planaguma J, Gil-Moreno A, Monge M, Gonzalez M, Baro T, Garcia A, Castellvi J, Ramon Y Cajal S, Xercavins J, Alameda F, Reventos J (2006) Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors. Histol Histopathol 21(2):197–204 https://doi.org/10.14670/HH-21.197
2. Agemy L, Friedmann-Morvinski D, Kotamraju VR, Roth L, Sugahara KN, Girard OM et al (2011) Targeted nanoparticle-enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci 108(42):17450–17455. https://doi.org/10.1073/pnas.1114518108
3. Alexiou GA, Vartholomatos E, Tsamis IK, Peponi E, Markopoulos G, Papathanasopoulou AV, Tasiou I, Ragos V, Tsekeris P, Kyritsis AP, Galani V (2019) Combination treatment for glioblastoma with temozolomide, DFMO and radiation. J BUON 24(1):397–404
4. Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H (2003) PTEN methylation and expression in glioblastomas. Acta Neuropathol 106(5):479–485. https://doi.org/10.1007/s00401-003-0748-4
5. Bahuau M, Vidaud D, Jenkins RB, Bièche I, Kimmel DW, Assouline B, Smith JS, Alderete B, Cayuela JM, Harpey JP, Caille B, Vidaud M (1998) Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Can Res 58(11):2298–2303